Onkologia Medikoa
Espezialitatea
Institut Universitaire de France
París, FranciaInstitut Universitaire de France-ko ikertzaileekin lankidetzan egindako argitalpenak (1)
2013
-
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): An open-label randomised study
The Lancet Oncology, Vol. 14, Núm. 10, pp. 962-970